ClinicalTrials.gg
CompletedNCT00141297Updated Jan 5, 2016Results posted

A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer

A Phase 1 interventional study of PD-0332991 in Neoplasms and Lymphoma, Non-Hodgkin, sponsored by Pfizer. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-01-05.

Primary conditionLymphoma, Non-HodgkinRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Non-Hodgkin
Why
  1. The study's listed conditions name Lymphoma, Non-Hodgkin, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
74
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Lymphoma, Non-Hodgkin by Pfizer — none open to participants now, none under way, none of them phase 3. Lymphoma, Non-Hodgkin · Pfizer.

Enrollment
13th of 28
74 · median 66
Started
2004
with 2 others
Phase 1
16 of 29
none open now
Registered
3rd of 29
by date

Among the 29 studies in Lymphoma, Non-Hodgkin by Pfizer, this one is the 13th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2004, is one of 16 in phase 1, and was the 3rd registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

None of the 29 studies in Lymphoma, Non-Hodgkin by Pfizer is open now. The open studies under Lymphoma, Non-Hodgkin, anywhere →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies in Lymphoma, Non-Hodgkin by Pfizer as a file.
02

Study summary

PD-0332991 may work in cancer by stopping cancer cells from multiplying. PD-0332991 is in a new class of drugs called cyclin-dependent kinase (CDK inhibitors). This research study is the first time that PD-0332991 will be given to people. PD-0332991 is taken by mouth daily.

03

Conditions studied

  • Neoplasms
  • Lymphoma, Non-Hodgkin

Browse trials for

Keywords

  • Advanced cancer
04

In context

Lymphoma, Non-Hodgkin Reclassified

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

This study's enrollment of 74 is above the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.

Browse Lymphoma, Non-Hodgkin studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Compared within Lymphoma, Non-Hodgkin, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Advanced solid tumors (excluding SCLC and retinoblastoma) or follicular of diffuse large cell non-Hodgkin's lymphoma, or cytologically proven at diagnosis which is to or intolerant of established therapy know to provide clinical benefit for their condition; tumors must express Rb
  • Adequate blood cell counts, kidney function and liver function and and score of 0, 1, or 2.
  • Patients may have to have tumor before and after treatment.

Exclusion criteria

Exclusion Criteria:

  • Prior stem cell or bone marrow transplant
  • Uncontrolled infection, unstable or sever intercurrent medical condition, or current drug or alcohol abuse
  • Active or unstable cardiac disease or history of heart attack within 6 months
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    PD-0332991

    Drug: PD-0332991

Interventions

  • Dose ranging study - evaluating two oral schedule: (1) 3/1 Schedule - PD-0332991 administered days 1-21 of a 28-day schedule, doses ranging from 25 to 150 mg once daily; (2) 2/1 Schedule - PD-0332991 administered days 1-14 of a 21-days schedule, doses ranging from 100 to 225 mg once daily

07

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-Limiting Toxicities (DLT)

    DLT: an adverse event occurring after initiation of PD 0332991 that met any following criteria: 1) Grade 4 hematologic toxicity (platelets less than \[\<\] 25000 per microliter (mcL), absolute neutrophil count \[ANC\] \<500/mcL, hemoglobin \[Hb\] \<6.5 gram per deciliter \[g/dL\]; 2) ANC \<1000/mcL associated with documented infection or fever greater than or equal to (\>=) 38.5 degrees Celsius; 3) \>=Grade 3 non-hematologic treatment-related toxicity. In an asymptomatic participant, Grade 3 corrected QT (QTc) prolongation (\>500 millisecond) (only if persisted with repeat testing and after correction of reversible causes \[electrolyte abnormalities or hypoxia\]); and 4) Inability to receive next dose of PD 0332991 within 1 week (+/-1 day) of last dose due to lack of hematologic recovery (platelets \<50000/mcL, ANC \<1000/mcL, and Hb \<8.0 g/dL) or due to prolonged non-hematologic toxicities of \>=Grade 3 severity. Occurrence of a DLT necessitated immediate interruption of scheduled study treatment.

    Time frame: Baseline up to 28 days

  2. Maximum Administered Dose (MAD)

    Three new evaluable participants were to be assessed at each new dose level. The minimum time that these participants were to be followed after starting treatment was 1 cycle (28 or 21 days) before a new dose level could be opened. If none of these 3 participants experienced a DLT, the next higher dose level was to be opened on that schedule. If 1 participant developed a DLT, 3 more evaluable participants were to be enrolled at that dose level; if none of these additional 3 participants developed a DLT, the next higher dose level was to be opened on that schedule. If \>=2 participants experienced a first cycle DLT at the same dose level and schedule, that dose level was to be defined as the MAD for that schedule. No additional participants were to be entered at the MAD for that dosing schedule. DLT is defined in Outcome Measure 1.

    Time frame: Baseline up to 28 days

  3. Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose Level (RP2D)

    MTD was defined as the highest dose level studied for which the incidence of first cycle DLT was \<33%. Once MTD was determined, it was defined as RP2D. DLT is defined in Outcome Measure 1.

    Time frame: Baseline up to 28 days

  4. Number of Dose-Limiting Toxicities (DLTs) Categorized as Per the Nature

    DLT is defined in Outcome Measure 1. Hematologic (Grade 4 \[life-threatening or disabling\]) and non-hematologic (Grade 3 \[severe\], 4 \[life-threatening and disabling\], 5 \[resulting in death\]) DLTs are reported separately. A single participant may experience more than one DLT. Both treatment-related and treatment-unrelated DLT events were reported for this outcome measure.

    Time frame: Baseline up to 28 days

  5. Number of Participants With Treatment Emergent Adverse Events Categorized by Severity

    An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. For clinical description of nature (severity) of AEs, AEs were grades as: Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening or disabling AE; and Grade 5: death related to AE. AEs during Cycle 1 and AEs post Cycle 1 are reported separately.

    Time frame: Cycle 1, Cycle 2 up to 28 days after end of treatment (up to Cycle 93)

  6. Number of Participants With Treatment-Related Treatment Emergent Adverse Events

    A treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs during Cycle 1 and AEs post Cycle 1 are reported separately.

    Time frame: Cycle 1, Cycle 2 up to 28 days after end of treatment (up to Cycle 93)

  7. Number of Participants Who Died Due to Adverse Event on the Basis of Relatedness to Study Drug

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness \[to study drug\] was assessed by the investigator (Yes/No).

    Time frame: Baseline up to 30 days after end of treatment (up to Cycle 93)

  8. Maximum Observed Plasma Concentration (Cmax) on Day 1: Single Dose

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 1 of Cycle 1 (C1D1)

  9. Maximum Observed Plasma Concentration (Cmax) on Day 8: Multiple Dose

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 8 of Cycle 1 (C1D8)

  10. Maximum Observed Plasma Concentration (Cmax) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose

    The mean Cmax for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D21 for participants receiving 125 mg (21/28 Days) and Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D14 for participants receiving 200 mg (14/21 Days)

  11. Maximum Observed Plasma Concentration (Cmax) on Day 1: Food Effect

    To determine the impact of food (specifically a high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In this crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. The first 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, the next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results are reported as per fed and fasted conditions. The high-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of the total caloric content.

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D1, C2D1

  12. Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1: Single Dose

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 1 of Cycle 1 (C1D1)

  13. Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 8: Multiple Dose

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 8 of Cycle 1 (C1D8)

  14. Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose

    The median Tmax for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D21 for participants receiving 125 mg (21/28 Days) and Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D14 for participants receiving 200 mg (14/21 Days)

  15. Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1: Food Effect

    To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results are reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D1, C2D1

  16. Terminal Half-life (t½ ) on Day 1: Single Dose

    Terminal half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 1 of Cycle 1 (C1D1)

  17. Terminal Half-life (t½ ) on Day 8: Multiple Dose

    Terminal half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 8 of Cycle 1 (C1D8)

  18. Terminal Half-life (t½) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose

    Terminal half-life is the time measured for the plasma concentration to decrease by one half. The mean t1/2 for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D21 for participants receiving 125 mg (21/28 Days) and Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D14 for participants receiving 200 mg (14/21 Days)

  19. Terminal Half-life (t½ ) on Day 1: Food Effect

    To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results were to be reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D1, C2D1

  20. Area Under the Curve From Time Zero to the Last Measured Concentration (AUClast) on Day 1: Single Dose

    Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 1 of Cycle 1 (C1D1)

  21. Area Under the Curve From Time Zero to the Last Measured Concentration (AUClast) on Day 8: Multiple Dose

    Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 8 of Cycle 1 (C1D8)

  22. Area Under the Curve From Time Zero to the Last Measured Concentration (AUClast) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose

    Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). The mean AUClast for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D21 for participants receiving 125 mg (21/28 Days) and Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D14 for participants receiving 200 mg (14/21 Days)

  23. Area Under the Curve From Time Zero to the Last Measured Concentration (AUClast) on Day 1: Food Effect

    Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results are reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D1, C2D1

  24. Area Under the Curve From Time Zero to End of the Dosing Interval [AUC(0 to Tau)] on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose

    Area under the curve from time zero to end of the dosing interval (24 hours) \[AUC (0-tau)\]. The mean AUC (0-tau) for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D21 for participants receiving 125 mg (21/28 Days) and Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D14 for participants receiving 200 mg (14/21 Days)

  25. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] on Day 1: Single Dose

    AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 1 of Cycle 1 (C1D1)

  26. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] on Day 8: Multiple Dose

    AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 8 of Cycle 1 (C1D8)

  27. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] on Day 1: Food Effect

    AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results were to be reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D1, C2D1

  28. Apparent Oral Clearance (CL/F) on Day 1: Single Dose

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 1 of Cycle 1 (C1D1)

  29. Apparent Oral Clearance (CL/F) on Day 8: Multiple Dose

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 8 of Cycle 1 (C1D8)

  30. Apparent Oral Clearance (CL/F) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose

    Clearance of a drug is a measure of rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. The mean CL/F for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D21 for participants receiving 125 mg (21/28 Days) and Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D14 for participants receiving 200 mg (14/21 Days)

  31. Apparent Oral Clearance (CL/F) on Day 1: Food Effect

    Clearance of a drug is a measure of rate at which a drug is metabolized or eliminated by normal biological processes. To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results were to be reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D1, C2D1

  32. Apparent Volume of Distribution (Vz/F) on Day 1: Single Dose

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 1 of Cycle 1 (C1D1)

  33. Apparent Volume of Distribution (Vz/F) on Day 8: Multiple Dose

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 8 of Cycle 1 (C1D8)

  34. Apparent Volume of Distribution (Vz/F) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed. The mean Vz/F for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D21 for participants receiving 125 mg (21/28 Days) and Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D14 for participants receiving 200 mg (14/21 Days)

  35. Apparent Volume of Distribution (Vz/F) on Day 1: Food Effect

    Volume of distribution: theoretical volume in which total amount of drug would need to be uniformly distributed to produce desired plasma concentration. To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results were to be reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D1, C2D1

  36. Accumulation Ratio (Rac) on Day 8: Multiple Dose

    Rac at Day 8 = AUC (0-tau) at Day 8 divided by AUC (0-tau) at Day 1.

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10, and 24 hours post-dose on C1D1 and C1D8

  37. Accumulation Ratio (Rac) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose

    Rac at Day 14/21 = AUC (0-tau) at Day 14/21 divided by AUC (0-tau) at Day 1. The mean Rac for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D21 for participants receiving 125 mg (21/28 Days) and Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D14 for participants receiving 200 mg (14/21 Days)

  38. Terminal Phase Rate Constant [Lambda (z)] on Day 1: Single Dose

    Terminal phase rate constant is the absolute value of the slope of a linear regression during the terminal phase of the natural--logarithm transformed concentration--time profile.

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 1 of Cycle 1 (C1D1)

  39. Terminal Phase Rate Constant [Lambda (z)] on Day 8: Multiple Dose

    Terminal phase rate constant is the absolute value of the slope of a linear regression during the terminal phase of the natural-logarithm transformed concentration-time profile.

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 8 of Cycle 1 (C1D8)

  40. Terminal Phase Rate Constant [Lambda (z)] on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose

    Terminal phase rate constant is the absolute value of the slope of a linear regression during the terminal phase of the natural-logarithm transformed concentration-time profile. The mean lambda (z) for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D21 for participants receiving 125 mg (21/28 Days) and Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D14 for participants receiving 200 mg (14/21 Days)

  41. Terminal Phase Rate Constant [Lambda (z)] on Day 1: Food Effect

    Terminal phase rate constant: absolute value of slope of a linear regression during terminal phase of natural-logarithm transformed concentration-time profile. To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results were to be reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.

    Time frame: Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D1, C2D1

  42. Cumulative Amount of Drug Recovered Unchanged in the Urine (Ae): Single Dose

    Ae is the cumulative amount of drug recovered unchanged in urine over the 10 hour collection interval. Cumulative amount was calculated as sum of urine drug concentration in sample volume for each collection interval. Urine PK analysis was performed only in the MTD/RP2D groups (125 mg \[21/28 Days\] and 200 mg \[14/21 Days\]).

    Time frame: Hour 0 (pre-dose) to 10 hours post-dose on C1D1

  43. Cumulative Amount of Drug Recovered Unchanged in the Urine (Ae): Food Effect

    The Ae is defined in Outcome Measure 42. To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results were to be reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.

    Time frame: Hour 0 (pre-dose) to 10 hours post-dose on C1D1

  44. Percent Dose Recovered Unchanged in Urine (Percent Ae): Single Dose

    Percent of dose recovered unchanged in urine over the 10 hour collection interval=100\*(Ae divided by dose). Ae is the cumulative amount of drug recovered unchanged in urine over the 10 hour collection interval. Cumulative amount was calculated as sum of urine drug concentration in sample volume for each collection interval.

    Time frame: Hour 0 (pre-dose) to 10 hours post-dose on C1D1

  45. Percent Dose Recovered Unchanged (Percent Ae) in Urine: Food Effect

    The percent Ae is defined in Outcome Measure 44. To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results were to be reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.

    Time frame: Hour 0 (pre-dose) to 10 hours post-dose on C1D1

  46. Number of Participants With Best Response

    Number of participants with best response. Complete response (CR): disappearance of all target and non-target lesions. Partial Response (PR): \>=30% decrease in sum of longest diameter (LD) of lesions taking as reference baseline sum LD and no unequivocal progression in non-target lesions. Progressive disease (PD): \>=20% increase in sum of LD of lesions taking as a reference smallest sum of the LD since treatment start, or the appearance of \>=1 new lesion or unequivocal progression of existing non-target lesions. Stable disease (SD): neither shrinkage for PR nor increase for PD taking as reference smallest sum of LD since treatment start. SD was assessed following the first 2 cycles of treatment (\>=2 cycles), 4 cycles of treatment (\>=4 cycles), and 10 cycles of treatment (\>=10 cycles). Participants may be reported in more than 1 category of SD. Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response.

    Time frame: Baseline up to end of treatment, assessed at C1D1, C1D8, C1D15, C1D22, thereafter Day 1, 8, 15, and 22 of every other cycle up to end of treatment (up to Cycle 93)

  47. Inhibition of Cyclin-dependent Kinases 4 and 6 (Cdk4/6) Based on Phosphorylated Retinoblastoma (p-Rb) in Tumor Tissue

    Phosphorylation of the retinoblastoma (Rb) protein by Cdk4/6 is typically required for human cancer cell proliferation. Tumor biopsies were to be performed, to demonstrate inhibition of Cdk4/6 based on reduction in phosphorylated Rb (p-Rb) in tumor tissue and p-Rb levels (fold decrease) were to be reported.

    Time frame: Baseline, C1D1, C1D8, C1D15, C1D22, thereafter Day 1, 8, 15, and 22 of every other cycle up to end of treatment (up to Cycle 93)

  48. Correlation of Cyclin-dependent Kinases 4 and 6 (Cdk4/6) With PD 0322991 Dose

    Phosphorylation of the retinoblastoma (Rb) protein by Cdk4/6 is typically required for human cancer cell proliferation. Tumor biopsies were to be performed, to demonstrate inhibition of Cdk4/6 based on reduction in phosphorylated Rb (p-Rb) in tumor tissue, in correlation with respect to PD 0322991 dose.

    Time frame: Baseline, C1D1, C1D8, C1D15, C1D22, thereafter Day 1, 8, 15, and 22 of every other cycle up to end of treatment (up to Cycle 93)

  49. Correlation of Cyclin-dependent Kinases 4 and 6 (Cdk4/6) With Exposure

    Phosphorylation of the retinoblastoma (Rb) protein by Cdk4/6 is typically required for human cancer cell proliferation. Tumor biopsies were to be performed, to demonstrate inhibition of Cdk4/6 based on reduction in phosphorylated Rb (p-Rb) in tumor tissue, in correlation with PD 0322991 exposure.

    Time frame: Baseline, C1D1, C1D8, C1D15, C1D22, thereafter Day 1, 8, 15, and 22 of every other cycle up to end of treatment (up to Cycle 93)

  50. Correlation of Cyclin-dependent Kinases 4 and 6 (Cdk4/6) With Tumor Response

    Phosphorylation of the retinoblastoma (Rb) protein by Cdk4/6 is typically required for human cancer cell proliferation. Tumor biopsies were to be performed, to demonstrate inhibition of Cdk4/6 based on reduction in phosphorylated Rb (p-Rb) in tumor tissue, in correlation with tumor response.

    Time frame: Baseline, C1D1, C1D8, C1D15, C1D22, thereafter Day 1, 8, 15, and 22 of every other cycle up to end of treatment (up to Cycle 93)

08

Results

Posted Oct 28, 2015

Participant flow

Participant flow — Overall Study
MilestonePD 0332991 25 mg QD (21/28 Days)PD 0332991 50 mg QD (21/28 Days)PD 0332991 75 mg QD (21/28 Days)PD 0332991 100 mg QD (21/28 Days)PD 0332991 125 mg QD (21/28 Days)PD 0332991 150 mg QD (21/28 Days)PD 0332991 100 mg QD (14/21 Days)PD 0332991 150 mg QD (14/21 Days)PD 0332991 200 mg QD (14/21 Days)PD 0332991 225 mg QD (14/21 Days)
Started337322334206
Completed0000000000
Not completed337322334206
Withdrew: Adverse event0010110110
Withdrew: Death1000000010
Withdrew: Withdrawal by subject0000000010
Withdrew: Other0001500020
Withdrew: Progressive disease236215233156
Withdrew: Transitioned0000100000

Outcome measures

PrimaryNumber of Participants With Dose-Limiting Toxicities (DLT)

DLT: an adverse event occurring after initiation of PD 0332991 that met any following criteria: 1) Grade 4 hematologic toxicity (platelets less than \[\<\] 25000 per microliter (mcL), absolute neutrophil count \[ANC\] \<500/mcL, hemoglobin \[Hb\] \<6.5 gram per deciliter \[g/dL\]; 2) ANC \<1000/mcL associated with documented infection or fever greater than or equal to (\>=) 38.5 degrees Celsius; 3) \>=Grade 3 non-hematologic treatment-related toxicity. In an asymptomatic participant, Grade 3 corrected QT (QTc) prolongation (\>500 millisecond) (only if persisted with repeat testing and after correction of reversible causes \[electrolyte abnormalities or hypoxia\]); and 4) Inability to receive next dose of PD 0332991 within 1 week (+/-1 day) of last dose due to lack of hematologic recovery (platelets \<50000/mcL, ANC \<1000/mcL, and Hb \<8.0 g/dL) or due to prolonged non-hematologic toxicities of \>=Grade 3 severity. Occurrence of a DLT necessitated immediate interruption of scheduled study treatment.

Time frame:
Baseline up to 28 days
Reported as:
Number · participants
Number of Participants With Dose-Limiting Toxicities (DLT)
participantsPD 0332991 25 mg QD (21/28 Days)PD 0332991 50 mg QD (21/28 Days)PD 0332991 75 mg QD (21/28 Days)PD 0332991 100 mg QD (21/28 Days)PD 0332991 125 mg QD (21/28 Days)PD 0332991 150 mg QD (21/28 Days)PD 0332991 100 mg QD (14/21 Days)PD 0332991 150 mg QD (14/21 Days)PD 0332991 200 mg QD (14/21 Days)PD 0332991 225 mg QD (14/21 Days)
Number of Participants With Dose-Limiting Toxicities (DLT)0020120043
PrimaryMaximum Administered Dose (MAD)

Three new evaluable participants were to be assessed at each new dose level. The minimum time that these participants were to be followed after starting treatment was 1 cycle (28 or 21 days) before a new dose level could be opened. If none of these 3 participants experienced a DLT, the next higher dose level was to be opened on that schedule. If 1 participant developed a DLT, 3 more evaluable participants were to be enrolled at that dose level; if none of these additional 3 participants developed a DLT, the next higher dose level was to be opened on that schedule. If \>=2 participants experienced a first cycle DLT at the same dose level and schedule, that dose level was to be defined as the MAD for that schedule. No additional participants were to be entered at the MAD for that dosing schedule. DLT is defined in Outcome Measure 1.

Time frame:
Baseline up to 28 days
Reported as:
Number · milligram
Maximum Administered Dose (MAD)
milligramPD 0332991 (21/28 Days)PD 0332991 (14/21 Days)
Maximum Administered Dose (MAD)150225
PrimaryMaximum Tolerated Dose (MTD)/Recommended Phase 2 Dose Level (RP2D)

MTD was defined as the highest dose level studied for which the incidence of first cycle DLT was \<33%. Once MTD was determined, it was defined as RP2D. DLT is defined in Outcome Measure 1.

Time frame:
Baseline up to 28 days
Reported as:
Number · milligram
Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose Level (RP2D)
milligramPD 0332991 (21/28 Days)PD 0332991 (14/21 Days)
Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose Level (RP2D)125200
PrimaryNumber of Dose-Limiting Toxicities (DLTs) Categorized as Per the Nature

DLT is defined in Outcome Measure 1. Hematologic (Grade 4 \[life-threatening or disabling\]) and non-hematologic (Grade 3 \[severe\], 4 \[life-threatening and disabling\], 5 \[resulting in death\]) DLTs are reported separately. A single participant may experience more than one DLT. Both treatment-related and treatment-unrelated DLT events were reported for this outcome measure.

Time frame:
Baseline up to 28 days
Reported as:
Number · DLTs
Number of Dose-Limiting Toxicities (DLTs) Categorized as Per the Nature
DLTsPD 0332991 25 mg QD (21/28 Days)PD 0332991 50 mg QD (21/28 Days)PD 0332991 75 mg QD (21/28 Days)PD 0332991 100 mg QD (21/28 Days)PD 0332991 125 mg QD (21/28 Days)PD 0332991 150 mg QD (21/28 Days)PD 0332991 100 mg QD (14/21 Days)PD 0332991 150 mg QD (14/21 Days)PD 0332991 200 mg QD (14/21 Days)PD 0332991 225 mg QD (14/21 Days)
Hematologic DLT: Grade 40010110001
Non-Hematologic DLT: Grade 30020500031
Non-Hematologic DLT: Grade 40000000101
Non-Hematologic DLT: Grade 50000001000
PrimaryNumber of Participants With Treatment Emergent Adverse Events Categorized by Severity

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. For clinical description of nature (severity) of AEs, AEs were grades as: Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening or disabling AE; and Grade 5: death related to AE. AEs during Cycle 1 and AEs post Cycle 1 are reported separately.

Time frame:
Cycle 1, Cycle 2 up to 28 days after end of treatment (up to Cycle 93)
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events Categorized by Severity
participantsPD 0332991 25 mg QD (21/28 Days)PD 0332991 50 mg QD (21/28 Days)PD 0332991 75 mg QD (21/28 Days)PD 0332991 100 mg QD (21/28 Days)PD 0332991 125 mg QD (21/28 Days)PD 0332991 150 mg QD (21/28 Days)PD 0332991 100 mg QD (14/21 Days)PD 0332991 150 mg QD (14/21 Days)PD 0332991 200 mg QD (14/21 Days)PD 0332991 225 mg QD (14/21 Days)
Cycle 1 TEAEs: Grade 10210712261
Cycle 1 TEAEs: Grade 21121500161
Cycle 1 TEAEs: Grade 30032710082
Cycle 1 TEAEs: Grade 40010110101
Cycle 1 TEAEs: Grade 50000001000
Post Cycle 1 TEAEs: Grade 10010800131
Post Cycle 1 TEAEs: Grade 20312311141
Post Cycle 1 TEAEs: Grade 32020321183
Post Cycle 1 TEAEs: Grade 40001000010
Post Cycle 1 TEAEs: Grade 51000000010
PrimaryNumber of Participants With Treatment-Related Treatment Emergent Adverse Events

A treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs during Cycle 1 and AEs post Cycle 1 are reported separately.

Time frame:
Cycle 1, Cycle 2 up to 28 days after end of treatment (up to Cycle 93)
Reported as:
Number · participants
Number of Participants With Treatment-Related Treatment Emergent Adverse Events
participantsPD 0332991 25 mg QD (21/28 Days)PD 0332991 50 mg QD (21/28 Days)PD 0332991 75 mg QD (21/28 Days)PD 0332991 100 mg QD (21/28 Days)PD 0332991 125 mg QD (21/28 Days)PD 0332991 150 mg QD (21/28 Days)PD 0332991 100 mg QD (14/21 Days)PD 0332991 150 mg QD (14/21 Days)PD 0332991 200 mg QD (14/21 Days)PD 0332991 225 mg QD (14/21 Days)
Cycle 1025316314195
Post Cycle 1134310323175
PrimaryNumber of Participants Who Died Due to Adverse Event on the Basis of Relatedness to Study Drug

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness \[to study drug\] was assessed by the investigator (Yes/No).

Time frame:
Baseline up to 30 days after end of treatment (up to Cycle 93)
Reported as:
Number · participants
Number of Participants Who Died Due to Adverse Event on the Basis of Relatedness to Study Drug
participantsPD 0332991 25 mg QD (21/28 Days)PD 0332991 50 mg QD (21/28 Days)PD 0332991 75 mg QD (21/28 Days)PD 0332991 100 mg QD (21/28 Days)PD 0332991 125 mg QD (21/28 Days)PD 0332991 150 mg QD (21/28 Days)PD 0332991 100 mg QD (14/21 Days)PD 0332991 150 mg QD (14/21 Days)PD 0332991 200 mg QD (14/21 Days)PD 0332991 225 mg QD (14/21 Days)
Related to Study Drug0000000000
Not Related to Study Drug1000301011
PrimaryMaximum Observed Plasma Concentration (Cmax) on Day 1: Single Dose
Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 1 of Cycle 1 (C1D1)
Reported as:
Mean · nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) on Day 1: Single Dose
nanogram per milliliter (ng/mL)PD 0332991 25 mg QD (21/28 Days)PD 0332991 50 mg QD (21/28 Days)PD 0332991 75 mg QD (21/28 Days)PD 0332991 100 mg QDPD 0332991 125 mg QD (21/28 Days)PD 0332991 150 mg QDPD 0332991 200 mg QD (14/21 Days)PD 0332991 225 mg QD (14/21 Days)
Maximum Observed Plasma Concentration (Cmax) on Day 1: Single Dose9.6 ± 6.020.7 ± 0.728.7 ± 6.945.6 ± 20.451.6 ± 22.283.8 ± 13.980.8 ± 28.4104.2 ± 60.7
PrimaryMaximum Observed Plasma Concentration (Cmax) on Day 8: Multiple Dose
Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 8 of Cycle 1 (C1D8)
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) on Day 8: Multiple Dose
ng/mLPD 0332991 25 mg QD (21/28 Days)PD 0332991 50 mg QD (21/28 Days)PD 0332991 75 mg QD (21/28 Days)PD 0332991 100 mg QDPD 0332991 125 mg QD (21/28 Days)PD 0332991 150 mg QDPD 0332991 200 mg QD (14/21 Days)PD 0332991 225 mg QD (14/21 Days)
Maximum Observed Plasma Concentration (Cmax) on Day 8: Multiple Dose15.9 ± 5.035.7 ± 5.758.6 ± 13.971.2 ± 22.286.2 ± 29.6160.8 ± 70.4173.6 ± 29.5185.7 ± 119.6
PrimaryMaximum Observed Plasma Concentration (Cmax) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose

The mean Cmax for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.

Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D21 for participants receiving 125 mg (21/28 Days) and Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D14 for participants receiving 200 mg (14/21 Days)
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose
ng/mLPD 0332991 200 mg (14/21 Days) and 125 mg (21/28 Days)
Maximum Observed Plasma Concentration (Cmax) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose104.0 ± 50.2
PrimaryMaximum Observed Plasma Concentration (Cmax) on Day 1: Food Effect

To determine the impact of food (specifically a high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In this crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. The first 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, the next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results are reported as per fed and fasted conditions. The high-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of the total caloric content.

Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D1, C2D1
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) on Day 1: Food Effect
ng/mLPD 0332991 200 mg (14/21 Days) and 125 mg (21/28 Days)
Fed62.0 ± 20.4
Fasted44.9 ± 14.4
PrimaryTime to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1: Single Dose
Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 1 of Cycle 1 (C1D1)
Reported as:
Median · hours
Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1: Single Dose
hoursPD 0332991 25 mg QD (21/28 Days)PD 0332991 50 mg QD (21/28 Days)PD 0332991 75 mg QD (21/28 Days)PD 0332991 100 mg QDPD 0332991 125 mg QD (21/28 Days)PD 0332991 150 mg QDPD 0332991 200 mg QD (14/21 Days)PD 0332991 225 mg QD (14/21 Days)
Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1: Single Dose4.0 (4.0 to 4.0)4.0 (4.0 to 4.3)4.0 (4.0 to 10.0)4.0 (2.0 to 10.0)7.0 (2.0 to 24.4)4.0 (4.0 to 9.8)5.7 (1.0 to 10.2)4.0 (4.0 to 7.0)
PrimaryTime to Reach Maximum Observed Plasma Concentration (Tmax) on Day 8: Multiple Dose
Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 8 of Cycle 1 (C1D8)
Reported as:
Median · hours
Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 8: Multiple Dose
hoursPD 0332991 25 mg QD (21/28 Days)PD 0332991 50 mg QD (21/28 Days)PD 0332991 75 mg QD (21/28 Days)PD 0332991 100 mg QDPD 0332991 125 mg QD (21/28 Days)PD 0332991 150 mg QDPD 0332991 200 mg QD (14/21 Days)PD 0332991 225 mg QD (14/21 Days)
Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 8: Multiple Dose4.0 (2.0 to 7.0)4.1 (2.0 to 7.0)4.0 (4.0 to 9.0)5.5 (4.0 to 10.0)4.0 (1.0 to 10.0)7.0 (7.0 to 10.0)4.0 (2.0 to 7.0)4.5 (1.0 to 7.0)
PrimaryTime to Reach Maximum Observed Plasma Concentration (Tmax) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose

The median Tmax for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.

Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D21 for participants receiving 125 mg (21/28 Days) and Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D14 for participants receiving 200 mg (14/21 Days)
Reported as:
Median · hours
Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose
hoursPD 0332991 200 mg (14/21 Days) and 125 mg (21/28 Days)
Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose4.2 (2.0 to 9.8)
PrimaryTime to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1: Food Effect

To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results are reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.

Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D1, C2D1
Reported as:
Median · hours
Time to Reach Maximum Observed Plasma Concentration (Tmax) on Day 1: Food Effect
hoursPD 0332991 200 mg (14/21 Days) and 125 mg (21/28 Days)
Fed7.00 (3.50 to 23.00)
Fasted7.00 (4.00 to 10.00)
PrimaryTerminal Half-life (t½ ) on Day 1: Single Dose

Terminal half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 1 of Cycle 1 (C1D1)

No measurements were reported for this outcome.

PrimaryTerminal Half-life (t½ ) on Day 8: Multiple Dose

Terminal half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 8 of Cycle 1 (C1D8)

No measurements were reported for this outcome.

PrimaryTerminal Half-life (t½) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose

Terminal half-life is the time measured for the plasma concentration to decrease by one half. The mean t1/2 for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.

Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D21 for participants receiving 125 mg (21/28 Days) and Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D14 for participants receiving 200 mg (14/21 Days)
Reported as:
Mean · hours
Terminal Half-life (t½) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose
hoursPD 0332991 200 mg (14/21 Days) and 125 mg (21/28 Days)
Terminal Half-life (t½) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose26.5 ± 7.0
PrimaryTerminal Half-life (t½ ) on Day 1: Food Effect

To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results were to be reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.

Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D1, C2D1

No measurements were reported for this outcome.

PrimaryArea Under the Curve From Time Zero to the Last Measured Concentration (AUClast) on Day 1: Single Dose

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).

Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 1 of Cycle 1 (C1D1)
Reported as:
Mean · nanogram*hour/milliliter (ng*hour/mL)
Area Under the Curve From Time Zero to the Last Measured Concentration (AUClast) on Day 1: Single Dose
nanogram*hour/milliliter (ng*hour/mL)PD 0332991 25 mg QD (21/28 Days)PD 0332991 50 mg QD (21/28 Days)PD 0332991 75 mg QD (21/28 Days)PD 0332991 100 mg QDPD 0332991 125 mg QD (21/28 Days)PD 0332991 150 mg QDPD 0332991 200 mg QD (14/21 Days)PD 0332991 225 mg QD (14/21 Days)
Area Under the Curve From Time Zero to the Last Measured Concentration (AUClast) on Day 1: Single Dose58 ± 29.5134 ± 7.2199 ± 40.5302 ± 119.6476 ± 281.1594 ± 118.11057 ± 570.5719 ± 396.7
PrimaryArea Under the Curve From Time Zero to the Last Measured Concentration (AUClast) on Day 8: Multiple Dose

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast).

Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 8 of Cycle 1 (C1D8)
Reported as:
Mean · ng*hour/mL
Area Under the Curve From Time Zero to the Last Measured Concentration (AUClast) on Day 8: Multiple Dose
ng*hour/mLPD 0332991 25 mg QD (21/28 Days)PD 0332991 50 mg QD (21/28 Days)PD 0332991 75 mg QD (21/28 Days)PD 0332991 100 mg QDPD 0332991 125 mg QD (21/28 Days)PD 0332991 150 mg QDPD 0332991 200 mg QD (14/21 Days)PD 0332991 225 mg QD (14/21 Days)
Area Under the Curve From Time Zero to the Last Measured Concentration (AUClast) on Day 8: Multiple Dose118 ± 38.3274 ± 41.8477 ± 122.7560 ± 183.1722 ± 265.31344 ± 565.31395 ± 315.61482 ± 935.1
PrimaryArea Under the Curve From Time Zero to the Last Measured Concentration (AUClast) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). The mean AUClast for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.

Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D21 for participants receiving 125 mg (21/28 Days) and Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D14 for participants receiving 200 mg (14/21 Days)
Reported as:
Mean · ng*hour/mL
Area Under the Curve From Time Zero to the Last Measured Concentration (AUClast) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose
ng*hour/mLPD 0332991 200 mg (14/21 Days) and 125 mg (21/28 Days)
Area Under the Curve From Time Zero to the Last Measured Concentration (AUClast) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose3626 ± 2565.8
PrimaryArea Under the Curve From Time Zero to the Last Measured Concentration (AUClast) on Day 1: Food Effect

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results are reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.

Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D1, C2D1
Reported as:
Mean · ng*hour/mL
Area Under the Curve From Time Zero to the Last Measured Concentration (AUClast) on Day 1: Food Effect
ng*hour/mLPD 0332991 200 mg (14/21 Days) and 125 mg (21/28 Days)
Fed809 ± 372.7
Fasted668 ± 280.6
PrimaryArea Under the Curve From Time Zero to End of the Dosing Interval [AUC(0 to Tau)] on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose

Area under the curve from time zero to end of the dosing interval (24 hours) \[AUC (0-tau)\]. The mean AUC (0-tau) for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.

Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D21 for participants receiving 125 mg (21/28 Days) and Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D14 for participants receiving 200 mg (14/21 Days)
Reported as:
Mean · ng*hour/mL
Area Under the Curve From Time Zero to End of the Dosing Interval [AUC(0 to Tau)] on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose
ng*hour/mLPD 0332991 200 mg (14/21 Days) and 125 mg (21/28 Days)
Area Under the Curve From Time Zero to End of the Dosing Interval [AUC(0 to Tau)] on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose1863 ± 1096.5
PrimaryArea Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] on Day 1: Single Dose

AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 1 of Cycle 1 (C1D1)

No measurements were reported for this outcome.

PrimaryArea Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] on Day 8: Multiple Dose

AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞).

Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 8 of Cycle 1 (C1D8)

No measurements were reported for this outcome.

PrimaryArea Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] on Day 1: Food Effect

AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results were to be reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.

Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D1, C2D1

No measurements were reported for this outcome.

PrimaryApparent Oral Clearance (CL/F) on Day 1: Single Dose

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 1 of Cycle 1 (C1D1)

No measurements were reported for this outcome.

PrimaryApparent Oral Clearance (CL/F) on Day 8: Multiple Dose

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 8 of Cycle 1 (C1D8)

No measurements were reported for this outcome.

PrimaryApparent Oral Clearance (CL/F) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose

Clearance of a drug is a measure of rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. The mean CL/F for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.

Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D21 for participants receiving 125 mg (21/28 Days) and Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D14 for participants receiving 200 mg (14/21 Days)
Reported as:
Mean · liter/hour
Apparent Oral Clearance (CL/F) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose
liter/hourPD 0332991 200 mg (14/21 Days) and 125 mg (21/28 Days)
Apparent Oral Clearance (CL/F) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose86.1 ± 42.8
PrimaryApparent Oral Clearance (CL/F) on Day 1: Food Effect

Clearance of a drug is a measure of rate at which a drug is metabolized or eliminated by normal biological processes. To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results were to be reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.

Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D1, C2D1

No measurements were reported for this outcome.

PrimaryApparent Volume of Distribution (Vz/F) on Day 1: Single Dose

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 1 of Cycle 1 (C1D1)

No measurements were reported for this outcome.

PrimaryApparent Volume of Distribution (Vz/F) on Day 8: Multiple Dose

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 8 of Cycle 1 (C1D8)

No measurements were reported for this outcome.

PrimaryApparent Volume of Distribution (Vz/F) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed. The mean Vz/F for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.

Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D21 for participants receiving 125 mg (21/28 Days) and Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D14 for participants receiving 200 mg (14/21 Days)
Reported as:
Mean · liter
Apparent Volume of Distribution (Vz/F) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose
literPD 0332991 200 mg (14/21 Days) and 125 mg (21/28 Days)
Apparent Volume of Distribution (Vz/F) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose3103 ± 1237.8
PrimaryApparent Volume of Distribution (Vz/F) on Day 1: Food Effect

Volume of distribution: theoretical volume in which total amount of drug would need to be uniformly distributed to produce desired plasma concentration. To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results were to be reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.

Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D1, C2D1

No measurements were reported for this outcome.

PrimaryAccumulation Ratio (Rac) on Day 8: Multiple Dose

Rac at Day 8 = AUC (0-tau) at Day 8 divided by AUC (0-tau) at Day 1.

Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, 10, and 24 hours post-dose on C1D1 and C1D8

No measurements were reported for this outcome.

PrimaryAccumulation Ratio (Rac) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose

Rac at Day 14/21 = AUC (0-tau) at Day 14/21 divided by AUC (0-tau) at Day 1. The mean Rac for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.

Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D21 for participants receiving 125 mg (21/28 Days) and Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D14 for participants receiving 200 mg (14/21 Days)
Reported as:
Mean · ratio
Accumulation Ratio (Rac) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose
ratioPD 0332991 200 mg (14/21 Days) and 125 mg (21/28 Days)
Accumulation Ratio (Rac) on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose2.5 ± 0.8
PrimaryTerminal Phase Rate Constant [Lambda (z)] on Day 1: Single Dose

Terminal phase rate constant is the absolute value of the slope of a linear regression during the terminal phase of the natural--logarithm transformed concentration--time profile.

Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 1 of Cycle 1 (C1D1)

No measurements were reported for this outcome.

PrimaryTerminal Phase Rate Constant [Lambda (z)] on Day 8: Multiple Dose

Terminal phase rate constant is the absolute value of the slope of a linear regression during the terminal phase of the natural-logarithm transformed concentration-time profile.

Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, and 10 hours post-dose on Day 8 of Cycle 1 (C1D8)

No measurements were reported for this outcome.

PrimaryTerminal Phase Rate Constant [Lambda (z)] on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose

Terminal phase rate constant is the absolute value of the slope of a linear regression during the terminal phase of the natural-logarithm transformed concentration-time profile. The mean lambda (z) for 200 mg dose group (dose corrected to 125 mg) on Cycle 1 Day 14 (C1D14) and 125 mg dose group on Cycle 1 Day 21 (C1D21) was calculated. Only participants from 125 mg and 200 mg dose groups were reported.

Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D21 for participants receiving 125 mg (21/28 Days) and Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D14 for participants receiving 200 mg (14/21 Days)
Reported as:
Mean · 1/hour
Terminal Phase Rate Constant [Lambda (z)] on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose
1/hourPD 0332991 200 mg (14/21 Days) and 125 mg (21/28 Days)
Terminal Phase Rate Constant [Lambda (z)] on Day 14/21 Dose-Corrected to 125 mg: Multiple Dose0.028 ± 0.0
PrimaryTerminal Phase Rate Constant [Lambda (z)] on Day 1: Food Effect

Terminal phase rate constant: absolute value of slope of a linear regression during terminal phase of natural-logarithm transformed concentration-time profile. To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results were to be reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.

Time frame:
Hour 0 (pre-dose), 1, 2, 4, 7, 10 and 24 hours post-dose on C1D1, C2D1

No measurements were reported for this outcome.

PrimaryCumulative Amount of Drug Recovered Unchanged in the Urine (Ae): Single Dose

Ae is the cumulative amount of drug recovered unchanged in urine over the 10 hour collection interval. Cumulative amount was calculated as sum of urine drug concentration in sample volume for each collection interval. Urine PK analysis was performed only in the MTD/RP2D groups (125 mg \[21/28 Days\] and 200 mg \[14/21 Days\]).

Time frame:
Hour 0 (pre-dose) to 10 hours post-dose on C1D1
Reported as:
Mean · microgram (mcg)
Cumulative Amount of Drug Recovered Unchanged in the Urine (Ae): Single Dose
microgram (mcg)PD 0332991 125 mg QD (21/28 Days)PD 0332991 200 mg QD (14/21 Days)
Cumulative Amount of Drug Recovered Unchanged in the Urine (Ae): Single Dose2191 ± 14043171 ± 2442
PrimaryCumulative Amount of Drug Recovered Unchanged in the Urine (Ae): Food Effect

The Ae is defined in Outcome Measure 42. To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results were to be reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.

Time frame:
Hour 0 (pre-dose) to 10 hours post-dose on C1D1

No measurements were reported for this outcome.

PrimaryPercent Dose Recovered Unchanged in Urine (Percent Ae): Single Dose

Percent of dose recovered unchanged in urine over the 10 hour collection interval=100\*(Ae divided by dose). Ae is the cumulative amount of drug recovered unchanged in urine over the 10 hour collection interval. Cumulative amount was calculated as sum of urine drug concentration in sample volume for each collection interval.

Time frame:
Hour 0 (pre-dose) to 10 hours post-dose on C1D1
Reported as:
Mean · percentage of dose
Percent Dose Recovered Unchanged in Urine (Percent Ae): Single Dose
percentage of dosePD 0332991 125 mg QD (21/28 Days)PD 0332991 200 mg QD (14/21 Days)
Percent Dose Recovered Unchanged in Urine (Percent Ae): Single Dose1.75 ± 1.11.59 ± 1.2
PrimaryPercent Dose Recovered Unchanged (Percent Ae) in Urine: Food Effect

The percent Ae is defined in Outcome Measure 44. To determine impact of food (specifically high-fat meal) on PD 0332991 PK, participants were tested under fed and fasted conditions in crossover fashion. Each participant served as their own control. In crossover fashion first dose was administered under either fed (high-fat meal) or fasted (10-hour fast) condition on Day 1 of Cycle 1 and 2. First 6 participants were tested under fed (on C1D1) followed by fasted (on C2D1) conditions, next 6 participants were tested under fasted (on C1D1) followed by fed (on C2D1) conditions. Only participants in PD 0332991 200 mg (14/21 days) and 125 mg (21/28 days) groups participated in food effect crossover and results were to be reported as per fed and fasted conditions. High-fat meal was composed of around 800 to 1000 calories total, with fat composing around 50% of total caloric content.

Time frame:
Hour 0 (pre-dose) to 10 hours post-dose on C1D1

No measurements were reported for this outcome.

PrimaryNumber of Participants With Best Response

Number of participants with best response. Complete response (CR): disappearance of all target and non-target lesions. Partial Response (PR): \>=30% decrease in sum of longest diameter (LD) of lesions taking as reference baseline sum LD and no unequivocal progression in non-target lesions. Progressive disease (PD): \>=20% increase in sum of LD of lesions taking as a reference smallest sum of the LD since treatment start, or the appearance of \>=1 new lesion or unequivocal progression of existing non-target lesions. Stable disease (SD): neither shrinkage for PR nor increase for PD taking as reference smallest sum of LD since treatment start. SD was assessed following the first 2 cycles of treatment (\>=2 cycles), 4 cycles of treatment (\>=4 cycles), and 10 cycles of treatment (\>=10 cycles). Participants may be reported in more than 1 category of SD. Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response.

Time frame:
Baseline up to end of treatment, assessed at C1D1, C1D8, C1D15, C1D22, thereafter Day 1, 8, 15, and 22 of every other cycle up to end of treatment (up to Cycle 93)
Reported as:
Number · participants
Number of Participants With Best Response
participantsPD 0332991 25 mg QD (21/28 Days)PD 0332991 50 mg QD (21/28 Days)PD 0332991 75 mg QD (21/28 Days)PD 0332991 100 mg QD (21/28 Days)PD 0332991 125 mg QD (21/28 Days)PD 0332991 150 mg QD (21/28 Days)PD 0332991 100 mg QD (14/21 Days)PD 0332991 150 mg QD (14/21 Days)PD 0332991 200 mg QD (14/21 Days)PD 0332991 225 mg QD (14/21 Days)
Confirmed CR0000000000
Confirmed PR0000000020
SD >=2 Cycles1211621053
SD >=4 Cycles1211321032
SD >=10 Cycles0111121011
PD216213023123
Not Assessable0000100010
PrimaryInhibition of Cyclin-dependent Kinases 4 and 6 (Cdk4/6) Based on Phosphorylated Retinoblastoma (p-Rb) in Tumor Tissue

Phosphorylation of the retinoblastoma (Rb) protein by Cdk4/6 is typically required for human cancer cell proliferation. Tumor biopsies were to be performed, to demonstrate inhibition of Cdk4/6 based on reduction in phosphorylated Rb (p-Rb) in tumor tissue and p-Rb levels (fold decrease) were to be reported.

Time frame:
Baseline, C1D1, C1D8, C1D15, C1D22, thereafter Day 1, 8, 15, and 22 of every other cycle up to end of treatment (up to Cycle 93)

No measurements were reported for this outcome.

PrimaryCorrelation of Cyclin-dependent Kinases 4 and 6 (Cdk4/6) With PD 0322991 Dose

Phosphorylation of the retinoblastoma (Rb) protein by Cdk4/6 is typically required for human cancer cell proliferation. Tumor biopsies were to be performed, to demonstrate inhibition of Cdk4/6 based on reduction in phosphorylated Rb (p-Rb) in tumor tissue, in correlation with respect to PD 0322991 dose.

Time frame:
Baseline, C1D1, C1D8, C1D15, C1D22, thereafter Day 1, 8, 15, and 22 of every other cycle up to end of treatment (up to Cycle 93)

No measurements were reported for this outcome.

PrimaryCorrelation of Cyclin-dependent Kinases 4 and 6 (Cdk4/6) With Exposure

Phosphorylation of the retinoblastoma (Rb) protein by Cdk4/6 is typically required for human cancer cell proliferation. Tumor biopsies were to be performed, to demonstrate inhibition of Cdk4/6 based on reduction in phosphorylated Rb (p-Rb) in tumor tissue, in correlation with PD 0322991 exposure.

Time frame:
Baseline, C1D1, C1D8, C1D15, C1D22, thereafter Day 1, 8, 15, and 22 of every other cycle up to end of treatment (up to Cycle 93)

No measurements were reported for this outcome.

PrimaryCorrelation of Cyclin-dependent Kinases 4 and 6 (Cdk4/6) With Tumor Response

Phosphorylation of the retinoblastoma (Rb) protein by Cdk4/6 is typically required for human cancer cell proliferation. Tumor biopsies were to be performed, to demonstrate inhibition of Cdk4/6 based on reduction in phosphorylated Rb (p-Rb) in tumor tissue, in correlation with tumor response.

Time frame:
Baseline, C1D1, C1D8, C1D15, C1D22, thereafter Day 1, 8, 15, and 22 of every other cycle up to end of treatment (up to Cycle 93)

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PD 0332991 25 mg QD (21/28 Days)—3/3 (100%)3/3 (100%)
PD 0332991 50 mg QD (21/28 Days)—1/3 (33.3%)3/3 (100%)
PD 0332991 75 mg QD (21/28 Days)—3/7 (42.9%)7/7 (100%)
PD 0332991 100 mg QD (21/28 Days)—1/3 (33.3%)3/3 (100%)
PD 0332991 125 mg QD (21/28 Days)—3/22 (13.6%)22/22 (100%)
PD 0332991 150 mg QD (21/28 Days)—0/3 (0%)3/3 (100%)
PD 0332991 100 mg QD (14/21 Days)—2/3 (66.7%)3/3 (100%)
PD 0332991 150 mg QD (14/21 Days)—3/4 (75%)4/4 (100%)
PD 0332991 200 mg QD (14/21 Days)—4/20 (20%)20/20 (100%)
PD 0332991 225 mg QD (14/21 Days)—1/6 (16.7%)6/6 (100%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventPD 0332991 25 mg QD (21/28 Days)PD 0332991 50 mg QD (21/28 Days)PD 0332991 75 mg QD (21/28 Days)PD 0332991 100 mg QD (21/28 Days)PD 0332991 125 mg QD (21/28 Days)PD 0332991 150 mg QD (21/28 Days)PD 0332991 100 mg QD (14/21 Days)PD 0332991 150 mg QD (14/21 Days)PD 0332991 200 mg QD (14/21 Days)PD 0332991 225 mg QD (14/21 Days)
HypotensionVascular disorders0/30/30/70/30/220/30/32/40/200/6
AnaemiaBlood and lymphatic system disorders1/30/30/70/30/220/30/30/40/200/6
Atrial fibrillationCardiac disorders0/30/30/70/30/220/31/30/40/200/6
Cardiac arrestCardiac disorders1/30/30/70/30/220/30/30/40/200/6
Abdominal painGastrointestinal disorders0/30/30/70/30/220/31/30/42/200/6
ConstipationGastrointestinal disorders0/31/31/70/30/220/30/31/40/200/6
Gastrointestinal haemorrhageGastrointestinal disorders1/30/30/70/30/220/30/30/40/200/6
Intestinal obstructionGastrointestinal disorders0/30/30/71/30/220/30/30/40/200/6
Oesophageal stenosisGastrointestinal disorders0/30/30/70/30/220/31/30/40/200/6
Small intestinal obstructionGastrointestinal disorders0/30/30/71/30/220/30/31/40/200/6
Most frequent other events
Showing 10 of 219
Most frequent other events
EventPD 0332991 25 mg QD (21/28 Days)PD 0332991 50 mg QD (21/28 Days)PD 0332991 75 mg QD (21/28 Days)PD 0332991 100 mg QD (21/28 Days)PD 0332991 125 mg QD (21/28 Days)PD 0332991 150 mg QD (21/28 Days)PD 0332991 100 mg QD (14/21 Days)PD 0332991 150 mg QD (14/21 Days)PD 0332991 200 mg QD (14/21 Days)PD 0332991 225 mg QD (14/21 Days)
NeutropeniaBlood and lymphatic system disorders0/32/34/73/38/223/30/30/412/203/6
FatigueGeneral disorders1/32/33/72/310/223/32/31/415/203/6
PainGeneral disorders0/33/31/71/30/220/32/30/44/200/6
AnaemiaBlood and lymphatic system disorders2/30/32/71/36/221/31/31/48/203/6
LeukopeniaBlood and lymphatic system disorders0/30/30/72/32/221/30/30/43/202/6
ConstipationGastrointestinal disorders0/32/32/71/35/220/32/32/46/201/6
DiarrhoeaGastrointestinal disorders0/32/33/71/34/220/32/31/49/202/6
FlatulenceGastrointestinal disorders0/30/31/72/32/220/32/30/43/200/6
NauseaGastrointestinal disorders0/32/32/72/36/222/31/31/411/201/6
VomitingGastrointestinal disorders0/31/31/72/36/221/31/31/43/200/6

Baseline characteristics

Full Analysis Set (FAS) included all enrolled participants who received at least one dose of study medication.

Age, Continuous
Age, Continuous(years)PD 0332991 (21/28 Days)PD 0332991 (14/21 Days)Total
Mean53.8 ± 13.159.9 ± 11.556.5 ± 12.7
Sex: Female, Male
Sex: Female, Male(Participants)PD 0332991 (21/28 Days)PD 0332991 (14/21 Days)Total
Female211738
Male201636
09

Study locations

4 sites
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Abramson Cancer Center Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Pharmacy/PCAM/West Pavillion
    Philadelphia, Pennsylvania 19104, United States
10

References and documents

Publications

  • Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009 Mar;9(3):153-66. doi: 10.1038/nrc2602. PubMed 19238148 ↗
  • Vaughn DJ, Flaherty K, Lal P, Gallagher M, O'Dwyer P, Wilner K, Chen I, Schwartz G. Treatment of growing teratoma syndrome. N Engl J Med. 2009 Jan 22;360(4):423-4. doi: 10.1056/NEJMc0808558. No abstract available. PubMed 19164198 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2004, a primary completion of Jul 2008 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2015, 7 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2005
First posted
Sep 1, 2005
Start
Sep 2004
Primary completionActual
Jul 2008
CompletionActual
Dec 2014
Results first posted
Oct 28, 2015
Last update
Jan 5, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00141297
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 1, 2005
Start date
Sep 2004
Primary completion
Jul 2008
Completion
Dec 2014
Results posted
Oct 28, 2015
Last update
Jan 5, 2016

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palbociclib

Start the discussion